OSMI-1: A Selective O-GlcNAc Transferase Inhibitor for Protein Modification Studies

Executive Summary: OSMI-1 is a small molecule inhibitor targeting O-GlcNAc transferase (OGT) with an IC50 of 2.7 μM in biochemical assays (source: product_spec). It reduces O-GlcNAcylation on proteins such as nucleoporin62 (Nup62), demonstrated by mass spectrometry (source: product_spec). OSMI-1 displays moderate acute toxicity in zebrafish (LC50 ~45–56 μM at 12–24 h; source: product_spec). The compound decreases CHO cell viability by ~50% at 50 μM over 24 h (source: product_spec). OSMI-1 is supplied by APExBIO at >98% purity, suitable for advanced O-GlcNAcylation research.

Biological Rationale

O-GlcNAcylation is a dynamic post-translational modification regulated by OGT and O-GlcNAcase (OGA). It modulates key cellular processes including transcription, signal transduction, and stress response (source: DOI). Disruption of O-GlcNAc cycling impacts mitochondrial homeostasis and is implicated in ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation. Abnormal O-GlcNAc modification has been linked to preeclampsia and other pregnancy-related disorders by destabilizing proteins like HUWE1, affecting trophoblast syncytialization (source: DOI).

Mechanism of Action of OSMI-1

OSMI-1 acts as a competitive inhibitor of OGT, preventing the transfer of N-acetylglucosamine to serine/threonine residues on target proteins. This inhibits global O-GlcNAcylation, as confirmed by immunoblotting and mass shift analysis of target proteins (source: product_spec). In cell-based assays, OSMI-1 reduces O-GlcNAc-modified Nup62 and lowers OGA levels, suggesting a feedback effect on the O-GlcNAc cycle. Its impact on O-GlcNAc homeostasis allows detailed dissection of protein modification pathways central to O-GlcNAcylation research and mitochondrial function (source: internal_article).

Evidence & Benchmarks

• OSMI-1 inhibits human OGT with an IC50 of 2.7 μM, measured by in vitro enzyme assay (source: product_spec).
• In CHO cells, 50 μM OSMI-1 results in ~50% reduction in viability after 24 h, indicating cytotoxicity at higher doses (source: product_spec).
• In zebrafish, the LC50 is 0.031 mg/mL (56 μM) at 12 h and 0.025 mg/mL (45 μM) at 24 h, reflecting moderate acute toxicity (source: product_spec).
• OSMI-1 reduces overall O-GlcNAcylation levels, with mass spectrometry confirming loss of O-GlcNAc residues on Nup62 (source: product_spec).
• Elevated O-GlcNAc modification stabilizes HUWE1, promoting TfR1 degradation and limiting ferroptosis in trophoblasts, as shown in murine and placental models (source: DOI).

For a detailed protocol-oriented comparison, see "OSMI-1: Redefining O-GlcNAc Transferase Inhibition in Placental Ferroptosis Research", which expands on in vivo applications and advanced mechanistic details not covered in this dossier.

Applications, Limits & Misconceptions

OSMI-1 is widely used in O-GlcNAcylation research to interrogate protein modification, ferroptosis, and mitochondrial homeostasis studies. In placental biology, it enables control of O-GlcNAc levels to model disease states such as preeclampsia (source: DOI). Its cell permeability and DMSO solubility facilitate use in diverse cell lines and model organisms. However, its cytotoxicity at higher doses requires careful titration in cellular assays. The molecule is not suitable for long-term solution storage or for use in water/ethanol-based vehicles due to solubility constraints (source: product_spec).

Common Pitfalls or Misconceptions

• OSMI-1 is not a direct OGA inhibitor; it specifically targets OGT (source: product_spec).
• Prolonged storage of OSMI-1 solutions, especially in aqueous buffers, leads to degradation (source: product_spec).
• High concentrations (>50 μM) are cytotoxic in many cell types and may confound results unrelated to O-GlcNAcylation (source: product_spec).
• OSMI-1 efficacy and toxicity profiles may not translate directly between species or cell types; empirical optimization is essential (workflow_recommendation).
• Interpretation of O-GlcNAc modification effects requires appropriate controls to distinguish direct versus compensatory cellular responses (workflow_recommendation).

For further reading on how OSMI-1 enables mitochondrial homeostasis and Parkin-dependent mitophagy research, see "OSMI-1: Advancing O-GlcNAc Transferase Inhibition in Ferroptosis Research". This article extends current knowledge by providing protocol guidance for advanced users.

Workflow Integration & Parameters

Protocol Parameters

• in vitro OGT inhibition assay | IC50 = 2.7 μM | purified enzyme | enables dose-response studies (source: product_spec)
• CHO cell viability | 50 μM, 24 h | cell cytotoxicity | defines upper concentration for cellular applications (source: product_spec)
• zebrafish toxicity | LC50 = 45–56 μM, 12–24 h | acute toxicity assessment | informs in vivo dose limits (source: product_spec)
• solubility | ≥50.6 mg/mL in DMSO | stock preparation | ensures compatibility with DMSO-based delivery (source: product_spec)
• storage | -20°C, avoid long-term solution storage | all workflows | maintains compound stability (source: product_spec)
• workflow optimization | titrate concentration and exposure time | experimental system-dependent | avoids off-target cytotoxicity (workflow_recommendation)

For precision O-GlcNAc transferase inhibition in cell models, see "OSMI-1: Precision O-GlcNAc Transferase Inhibition in Cell Models". This resource clarifies best practices for robust and reproducible experiments, which complements the current article's focus on comparative benchmarks.

Conclusion & Outlook

OSMI-1, supplied by APExBIO, is a validated small molecule O-GlcNAc transferase inhibitor with robust in vitro and in vivo characterization. Its use has enabled direct mechanistic insights into O-GlcNAc modification’s role in ferroptosis, trophoblast biology, and protein regulation. The compound’s limitations—chiefly cytotoxicity at higher doses and solvent constraints—are well-documented, ensuring predictable integration into O-GlcNAcylation research. Ongoing studies continue to leverage OSMI-1 to dissect the O-GlcNAc–HUWE1–TfR1 axis and its implications for pregnancy-associated diseases, as detailed in recent peer-reviewed literature (source: DOI).